Electrophysiological effects of E 4031, a drug with selective Class III properties, in man

PACE - Pacing and Clinical Electrophysiology

Volumn 20, Issue 4 I, 1997, Pages 930-937

  Katritsis, Demosthenes ^a,d   Morgan, John ^b   Brachmann, Johannes ^c   Bygrave, Angela ^a   O'Farrell, Dympna ^a   Rowland, Edward ^a   Camm, A John ^a  

^a St George's Hospital   (Germany)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

antiarrhythmic drugs; Class III; E 4031

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE;

ADULT; AGED; ARTICLE; BASOPHILIA; DRUG EFFECT; DRUG SAFETY; EOSINOPHILIA; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FUNCTION; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE FUNCTION; HUMAN; MALE; PAIN; REENTRY ARRHYTHMIA; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FUNCTION; ATRIOVENTRICULAR NODE; CARDIAC PACING, ARTIFICIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; HEART ATRIA; HEART CONDUCTION SYSTEM; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PYRIDINES;

EID: 0030958179     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1997.tb05496.x     Document Type: Article

References (17)

1. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
2. Morganroth J, Coin JE. Quinidine-related mortality in the short- to medium-term treatment of ventricular arrhythmias: A meta-analysis. Circulation 1991; 84:1977-1983.
3. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized controlled trials. Circulation 1990; 82:1106-1116.
4. Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989; 111:107-111.
5. Katritsis D, Camm AJ. Amiodarone in long term prophylaxis. Drugs 1991; 41(Suppl. 2):54-66.
6. Camm AJ, Katritsis D. How to prescribe and manage antiarrhythmic drug therapy. Eur Heart J 1992; 13(Suppl. F):44-52.
7. Mason JW, for the Electrophysiologic Study Versus Electrocardiographic Monitoring Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 1993; 329:445-451.
8. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993; 72: 280-287.
9. Russell DC, Oliver MF. Ventricular refractoriness during acute myocardial ischaemia and its relationship to ventricular fibrillation. Cardiovasc Res 1978; 12:221-227.
10. Zuanetti G, Corr PB. Selective prolongation of repolarization prevents sustained ventricular tachycardia in dogs with previous myocardial infarction. Evaluation with three-dimensional mapping. Circulation 1990; 82 (Suppl. III):III-64.
11. Mihara M, Tomoto Y, Hasegawa J, et al. Pharmacokinetics and bioavailabilty of a new class III antiarrhythmic drug (E4031) in healthy volunteers. (abstract) Cardiovasc Drugs Ther 1991;(Suppl. 3):394.
12. Lynch JL, Heaney LA, Wallace AA, et al. Suppression of lethal ischemic ventricular arrhythmias by the class III agent E4031 in a canine model of previous myocardial infarction. J Cardiovasc Pharmacol 1990; 15:764-775.
13. Sanguinetti MC, Jurkiewicz NK, Scott A, et al. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Mechanism of action. Circ Res 1991; 68:77-84.
14. + current: Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990; 96:194-214.
15. Argenticri TM, Carroll MS, Sullivan ME. Cellular electrophysiological effects of the class III antiarrhythmic agents sematilide and clofilium on rabbit atrial tissue. J Cardiovasc Pharmacol 1991; 18: 167-174.
16. Baskin EP, Serin CM, Wallace AA, et al. Effects of new and potent methanesulfonalide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscle. J Cardiovasc Pharmacol 1991; 18:406-414.
17. Roden DM. Current status of class III antiarrhythmic drug therapy. Am J Cardiol 1993; 72:44B-49B.